We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Argenta Expands Collaboration with Genentech to Include BioFocus

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Expands Collaboration with Genentech to Include BioFocus"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Argenta, a service division of Galapagos NV, has announced it has signed a contract extension with Genentech, Inc., a member of the Roche Group. The extended agreement expands the portfolio of projects which are in collaboration with Genentech and allows Genentech to place projects directly into Galapagos’ other service division, BioFocus.

Argenta’s collaboration with Genentech dates back to 2005. The current agreement covers a number of drug discovery programs that utilize Argenta's expertise in computer-aided drug design (CADD), medicinal chemistry, and in vitro biology and screening to discover new chemical entities acting against undisclosed drug targets defined by Genentech. Under the amendment, BioFocus will provide Genentech with integrated medicinal chemistry, in vitro biology and ADME services.

“We are delighted that Genentech has expanded its small-molecule drug discovery outsourcing into BioFocus, and we regard it as testament to the complementary expertise and technological capabilities that Argenta and BioFocus possess,” said Chris Newton, Senior Vice President, Galapagos Services.